177 related articles for article (PubMed ID: 36208441)
41. Biological activity of tumor-treating fields in preclinical glioma models.
Silginer M; Weller M; Stupp R; Roth P
Cell Death Dis; 2017 Apr; 8(4):e2753. PubMed ID: 28425987
[TBL] [Abstract][Full Text] [Related]
42. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
43. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
44. Rationale and Background on Tumor-Treating Fields for Glioblastoma.
Schwartz MA; Onuselogu L
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S20-4. PubMed ID: 27668387
[TBL] [Abstract][Full Text] [Related]
45. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
Pambid MR; Berns R; Adomat HH; Hu K; Triscott J; Maurer N; Zisman N; Ramaswamy V; Hawkins CE; Taylor MD; Dunham C; Guns E; Dunn SE
Pediatr Blood Cancer; 2014 Jan; 61(1):107-15. PubMed ID: 23940083
[TBL] [Abstract][Full Text] [Related]
46. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
Karanam NK; Srinivasan K; Ding L; Sishc B; Saha D; Story MD
Cell Death Dis; 2017 Mar; 8(3):e2711. PubMed ID: 28358361
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields).
Kirson ED; Schneiderman RS; Dbalý V; Tovarys F; Vymazal J; Itzhaki A; Mordechovich D; Gurvich Z; Shmueli E; Goldsher D; Wasserman Y; Palti Y
BMC Med Phys; 2009 Jan; 9():1. PubMed ID: 19133110
[TBL] [Abstract][Full Text] [Related]
48. Classic and desmoplastic medulloblastoma: complete case reports and characterizations of two new cell lines.
Holthouse DJ; Dallas PB; Ford J; Fabian V; Murch AR; Watson M; Wong G; Bertram C; Egli S; Baker DL; Kees UR
Neuropathology; 2009 Aug; 29(4):398-409. PubMed ID: 19077040
[TBL] [Abstract][Full Text] [Related]
49. Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.
Wu H; Yang L; Liu H; Zhou D; Chen D; Zheng X; Yang H; Li C; Chang J; Wu A; Wang Z; Ren N; Lv S; Liu Y; Jia M; Lu J; Liu H; Sun G; Liu Z; Liu J; Chen L
CNS Neurosci Ther; 2021 Dec; 27(12):1587-1604. PubMed ID: 34710276
[TBL] [Abstract][Full Text] [Related]
50. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
[TBL] [Abstract][Full Text] [Related]
51. EphrinB1 expression is dysregulated and promotes oncogenic signaling in medulloblastoma.
McKinney N; Yuan L; Zhang H; Liu J; Cho YJ; Rushing E; Schniederjan M; MacDonald TJ
J Neurooncol; 2015 Jan; 121(1):109-18. PubMed ID: 25258252
[TBL] [Abstract][Full Text] [Related]
52. An Overview of Sub-Cellular Mechanisms Involved in the Action of TTFields.
Tuszynski JA; Wenger C; Friesen DE; Preto J
Int J Environ Res Public Health; 2016 Nov; 13(11):. PubMed ID: 27845746
[TBL] [Abstract][Full Text] [Related]
53. Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment.
Carrieri FA; Smack C; Siddiqui I; Kleinberg LR; Tran PT
Front Oncol; 2020; 10():575992. PubMed ID: 33215030
[TBL] [Abstract][Full Text] [Related]
54. Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer
Jang Y; Lee WS; Sai S; Kim JY; Kim JK; Kim EH
Oncol Lett; 2022 Oct; 24(4):338. PubMed ID: 36039063
[TBL] [Abstract][Full Text] [Related]
55. Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.
Guo X; Yang X; Wu J; Yang H; Li Y; Li J; Liu Q; Wu C; Xing H; Liu P; Wang Y; Hu C; Ma W
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954334
[TBL] [Abstract][Full Text] [Related]
56. Tumor Treating Fields in the Management of Patients with Malignant Gliomas.
Ghiaseddin AP; Shin D; Melnick K; Tran DD
Curr Treat Options Oncol; 2020 Jul; 21(9):76. PubMed ID: 32734509
[TBL] [Abstract][Full Text] [Related]
57. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo.
Voloshin T; Munster M; Blatt R; Shteingauz A; Roberts PC; Schmelz EM; Giladi M; Schneiderman RS; Zeevi E; Porat Y; Bomzon Z; Urman N; Itzhaki A; Cahal S; Kirson ED; Weinberg U; Palti Y
Int J Cancer; 2016 Dec; 139(12):2850-2858. PubMed ID: 27561100
[TBL] [Abstract][Full Text] [Related]
58. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
Schneiderman RS; Shmueli E; Kirson ED; Palti Y
BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
[TBL] [Abstract][Full Text] [Related]
59. Evaluating the therapeutic effect of tumor treating fields (TTFields) by monitoring the impedance across TTFields electrode arrays.
Li X; Oziel M; Rubinsky B
PeerJ; 2022; 10():e12877. PubMed ID: 35186474
[TBL] [Abstract][Full Text] [Related]
60. Exosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastoma.
Zhu L; Yang Y; Li H; Xu L; You H; Liu Y; Liu Z; Liu X; Zheng D; Bie J; Li J; Song C; Yang B; Luo J; Chang Q
Cancer Lett; 2022 Jun; 535():215630. PubMed ID: 35304257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
